Sector News

GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots

October 22, 2014
Life sciences
With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline–and, fittingly, for its top management ranks, too.
 
At the center: R&D chief Moncef Slaoui will shift over to chair the vaccines unit–soon to be bolstered by a $7.1 buyout of most of the Swiss pharma’s vaccines portfolio–effective immediately. Patrick Vallance, who had run R&D on a day-to-day basis, will be stepping in to take the reins.
 
Slaoui, who radically altered the British drugmaker’s drug development process with a reorg focused on small units of scientists, “will take more focused accountability for vaccines, ensuring we fully leverage the value of his knowledge and experience,” a GSK spokeswoman Mary Anne Rhyne told FiercePharma by email.
 
The move is part of an effort to “ensure that our leaders are focused and aligned” around pharmaceuticals, vaccines and consumer healthcare–another business that will get a boost from the Novartis swap as the companies team up on a joint venture. GSK’s consumer health president, Emma Walmsley, will be heading up that partnership, with Glaxo controlling a 63.5% stake.
 
On the pharma side, emerging markets chief Abbas Hussain–who, if you’ll recall, last year publicly apologized to China’s government and offered price cuts in penance for the company’s $489 million doctor bribery scandal–will assume the role of global pharmaceuticals president, and he’ll have North American pharma president Dierdre Connelly reporting to him, Rhyne said.
 
And they’ll have their work cut out for them: In the third quarter, Glaxo reported pharmaceutical sales down 12% in the U.S., thanks in part to an 18% respiratory plunge. Megablockbuster Advair powered that decline, with increased competition helping take a 25% bite out of the aging behemoth’s top-line haul.
 
By Carly Helfand
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend